Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IASO Forms Collaboration with Umoja for Allogenic CAR-T Therapies

publication date: Nov 21, 2022

Shanghai IASO Bio formed a research collaboration with Umoja Biopharma of Seattle to test the efficacy of Umoja's iCIL off-the-shelf cell therapy platform with IASO’s CAR candidates. Umoja's allogeneic stem cell-based cell therapy platform uses a proprietary manufacturing process to direct differentiation and expansion of iCILs, a novel class of innate lymphocytes with potent anti-tumor activity. Initially, the companies will work to develop off-the-shelf therapies for patients with acute myeloid leukemia. IASO’s lead product is an autologous BCMA CAR-T currently at NDA stage in China that IASO partners with Eli Lilly. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital